Respiratory syncytial virus infection and immunity

Reviews in Medical Virology

Volumn 22, Issue 4, 2012, Pages 230-244

  González, Pablo A ^a   Bueno, Susan M ^a   Carreño, Leandro J ^a   Riedel, Claudia A ^a,c   Kalergis, Alexis M ^a,b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BCG VACCINE; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS PROTEIN;

ANTIGEN SPECIFICITY; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DENDRITIC CELL; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOGENESIS; INFECTION PREVENTION; INFLAMMATORY CELL; LUNG ALVEOLUS MACROPHAGE; LYMPHOCYTE FUNCTION; LYMPHOCYTE MIGRATION; MEMORY T LYMPHOCYTE; NONHUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; POLARIZATION; PROTEIN EXPRESSION; REINFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH2 CELL; UPREGULATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; HUMANS; IMMUNITY; LUNG; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES;

EID: 84863538415     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1704     Document Type: Review

References (132)

1. Storey S. Respiratory syncytial virus market. Nature Reviews. Drug Discovery 2010; 9: 15-16.
2. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. American Journal of Diseases of Children 1986; 140: 543-546.
3. Henderson FW, Collier AM, Clyde WA Jr, et al. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. The New England Journal of Medicine 1979; 300: 530-534.
4. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. Journal of Pediatrics 2003; 143: S112-S117.
5. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-1555.
6. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature Medicine 2001; 7: 719-724.
7. Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database of Systematic Reviews 2007; 1: CD000181.
8. Murata Y. Respiratory syncytial virus infection in adults. Current Opinion in Pulmonary Medicine 2008; 14: 235-240.
9. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatric Infectious Disease Journal 2003; 22: S76-S82.
10. Eisenhut M. Extrapulmonary manifestations of severe RSV bronchiolitis. Lancet 2006; 368: 988.
11. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection-a systematic review. Critical Care 2006; 10: R107.
12. Thorburn K, Hart CA. Think outside the box: extrapulmonary manifestations of severe respiratory syncytial virus infection. Critical Care 2006; 10: 159.
13. Le Nouen C, Hillyer P, Munir S, et al. Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells. PLoS One 2010; 5: e15017.
14. Kawasaki Y, Hosoya M, Katayose M, et al. Role of serum neutralizing antibody in reinfection of respiratory syncytial virus. Pediatrics International 2004; 46: 126-129.
15. Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. Journal of Infectious Diseases 1991; 163: 693-698.
16. Handforth J, Friedland JS, Sharland M. Basic epidemiology and immunopathology of RSV in children. Paediatric Respiratory Reviews 2000; 1: 210-214.
17. Dakhama A, Vitalis TZ, Hegele RG. Persistence of respiratory syncytial virus (RSV) infection and development of RSV-specific IgG1 response in a guinea-pig model of acute bronchiolitis. European Respiratory Journal 1997; 10: 20-26.
18. Collarini EJ, Lee FE, Foord O, et al. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. Journal of Immunology 2009; 183: 6338-6345.
19. Bukreyev A, Yang L, Fricke J, et al. The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes. Journal of Virology 2008; 82: 12191-12204.
20. Zhou J, Yang XQ, Fu Z, et al. Increased pathogenesis and inflammation of airways from respiratory syncytial virus infection in T cell deficient nude mice. Medical Microbiology and Immunology 2008; 197: 345-351.
21. Bueno SM, Gonzalez PA, Cautivo KM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 20822-20827.
22. Bueno SM, Gonzalez PA, Pacheco R, et al. Host immunity during RSV pathogenesis. International Immunopharmacology 2008; 8: 1320-1329.
23. Gonzalez PA, Bueno SM, Riedel CA, et al. Impairment of T cell immunity by the respiratory syncytial virus: targeting virulence mechanisms for therapy and prophylaxis. Current Medicinal Chemistry 2009; 16: 4609-4625.
24. Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. Journal of Immunology 2008; 181: 7958-7968.
25. Graham BS, Bunton LA, Wright PF, et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. The Journal of Clinical Investigation 1991; 88: 1026-1033.
26. King JC Jr, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. The Pediatric Infectious Disease Journal 1993; 12: 733-739.
27. Kruijsen D, Bakkers MJ, van Uden NO, et al. Serum antibodies critically affect virus-specific CD4(+)/CD8(+) T cell balance during respiratory syncytial virus infections. Journal of Immunology 2010; 185: 6489-6498.
28. Cautivo KM, Bueno SM, Cortes CM, et al. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant Bacillus Calmette-Guerin promotes virus clearance and protects from infection. Journal of Immunology 2010; 185: 7633-7645.
29. Tregoning JS, Yamaguchi Y, Harker J, et al. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. Journal of Virology 2008; 82: 4115-4124.
30. Beckham JD, Cadena A, Lin J, et al. Respiratory viral infections in patients with chronic, obstructive pulmonary disease. Journal of Infection 2005; 50: 322-330.
31. Chang J, Braciale TJ. Respiratory syncytial virus infection suppresses lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in the respiratory tract. Nature Medicine 2002; 8: 54-60.
32. Chang J, Choi SY, Jin HT, et al. Improved effector activity and memory CD8 T cell development by IL-2 expression during experimental respiratory syncytial virus infection. Journal of Immunology 2004; 172: 503-508.
33. Carreno LJ, Gonzalez PA, Bueno SM, et al. Modulation of the dendritic cell-T-cell synapse to promote pathogen immunity and prevent autoimmunity. Immunotherapy 2011; 3: 6-11.
34. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. The Journal of Experimental Medicine 2008; 205: 323-329.
35. Telcian AG, Laza-Stanca V, Edwards MR, et al. RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. Journal of Infectious Diseases 2011; 203: 85-94.
36. Tourdot S, Mathie S, Hussell T, et al. Respiratory syncytial virus infection provokes airway remodelling in allergen-exposed mice in absence of prior allergen sensitization. Clinical and Experimental Allergy 2008; 38: 1016-1024.
37. DiNapoli JM, Murphy BR, Collins PL, et al. Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virology Journal 2008; 5: 105.
38. Vallbracht S, Unsold H, Ehl S. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. European Journal of Immunology 2006; 36: 1434-1442.
39. Munir S, Hillyer P, Le Nouen C, et al. Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response. PLoS Pathogens 2011; 7: e1001336.
40. Varga SM, Wang X, Welsh RM, et al. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells. Immunity 2001; 15: 637-646.
41. Bueno SM, Gonzalez PA, Carreno LJ, et al. The capacity of Salmonella to survive inside dendritic cells and prevent antigen presentation to T cells is host specific. Immunology 2008; 4: 522-533.
42. Tobar JA, Carreno LJ, Bueno SM, et al. Virulent Salmonella enterica serovar Typhimurium evades adaptive immunity by preventing dendritic cells from activating T cells. Infection and Immunity 2006; 74: 6438-6448.
43. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. Journal of Biochemistry 2007; 141: 137-145.
44. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Current Topics in Microbiology and Immunology 2006; 311: 17-58.
45. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
46. Guerrero-Plata A, Casola A, Suarez G, et al. Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. American Journal of Respiratory Cell and Molecular Biology 2006; 34: 320-329.
47. Gonzalez PA, Prado CE, Leiva ED, et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 14999-15004.
48. Le Nouen C, Munir S, Losq S, et al. Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3. Virology 2009; 385: 169-182.
49. de Graaff PM, de Jong EC, van Capel TM, et al. Respiratory syncytial virus infection of monocyte-derived dendritic cells decreases their capacity to activate CD4 T cells. Journal of Immunology 2005; 175: 5904-5911.
50. Johnson TR, Johnson CN, Corbett KS, et al. Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus. PLoS One 2011; 6: e16458.
51. Boogaard I, van Oosten M, van Rijt LS, et al. Respiratory syncytial virus differentially activates murine myeloid and plasmacytoid dendritic cells. Immunology 2007; 122: 65-72.
52. Rothoeft T, Fischer K, Zawatzki S, et al. Differential response of human naive and memory/effector T cells to dendritic cells infected by respiratory syncytial virus. Clinical and Experimental Immunology 2007; 150: 263-273.
53. Chi B, Dickensheets HL, Spann KM, et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. Journal of Virology 2006; 80: 5032-5040.
54. Bartz H, Turkel O, Hoffjan S, et al. Respiratory syncytial virus decreases the capacity of myeloid dendritic cells to induce interferon-gamma in naive T cells. Immunology 2003; 109: 49-57.
55. Thornburg NJ, Shepherd B, Crowe JE Jr. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. Journal of Virology 2010; 84: 12895-12902.
56. Mukherjee S, Lindell DM, Berlin AA, et al. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. The American Journal of Pathology 2011; 179: 248-258.
57. Moore ML, Newcomb DC, Parekh VV, et al. STAT1 negatively regulates lung basophil IL-4 expression induced by respiratory syncytial virus infection. Journal of Immunology 2009; 183: 2016-2026.
58. Lukens MV, Kruijsen D, Coenjaerts FE, et al. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. Journal of Virology 2009; 83: 7235-7243.
59. Smit JJ, Lindell DM, Boon L, et al. The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS One 2008; 3: e1720.
60. Gill MA, Palucka AK, Barton T, et al. Mobilization of plasmacytoid and myeloid dendritic cells to mucosal sites in children with respiratory syncytial virus and other viral respiratory infections. Journal of Infectious Diseases 2005; 1991: 1105-1115.
61. Wang H, Peters N, Laza-Stanca V, et al. Local CD11c+ MHC class II- precursors generate lung dendritic cells during respiratory viral infection, but are depleted in the process. Journal of Immunology 2006; 177: 2536-2542.
62. Guerrero-Plata A, Kolli D, Hong C, et al. Subversion of pulmonary dendritic cell function by paramyxovirus infections. Journal of Immunology 2009; 182: 3072-83.
63. Wang H, Peters N, Schwarze J. Plasmacytoid dendritic cells limit viral replication, pulmonary inflammation, and airway hyperresponsiveness in respiratory syncytial virus infection. Journal of Immunology 2006; 177: 6263-6270.
64. Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. The Journal of Experimental Medicine 2006; 203: 1153-1159.
65. Munir S, Le Nouen C, Luongo C, et al. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. Journal of Virology 2008; 82: 8780-8796.
66. Spann KM, Tran KC, Collins PL. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. Journal of Virology 2005; 79: 5353-5362.
67. Elliott J, Lynch OT, Suessmuth Y, et al. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. Journal of Virology 2007; 81: 3428-3436.
68. Jie Z, Dinwiddie DL, Senft AP, et al. Regulation of STAT signaling in mouse bone marrow derived dendritic cells by respiratory syncytial virus. Virus Research 2011; 156: 127-133.
69. Kallal LE, Schaller MA, Lindell DM, et al. CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. European Journal of Immunology 2010; 40: 1042-1052.
70. Dustin ML. T-cell activation through immunological synapses and kinapses. Immunological Reviews 2008; 221: 77-89.
71. Carreno LJ, Riquelme EM, Gonzalez PA, et al. T-cell antagonism by short half-life pMHC ligands can be mediated by an efficient trapping of T-cell polarization toward the APC. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 210-215.
72. Schlender J, Walliser G, Fricke J, et al. Respiratory syncytial virus fusion protein mediates inhibition of mitogen-induced T-cell proliferation by contact. Journal of Virology 2002; 76: 1163-1170.
73. Maldonado RA, Irvine DJ, Schreiber R, et al. A role for the immunological synapse in lineage commitment of CD4 lymphocytes. Nature 2004; 431: 527-532.
74. Rothoeft T, Gonschorek A, Bartz H, et al. Antigen dose, type of antigen-presenting cell and time of differentiation contribute to the T helper 1/T helper 2 polarization of naive T cells. Immunology 2003; 110: 430-439.
75. Bromley SK, Peterson DA, Gunn MD, et al. Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. Journal of Immunology 2000; 165: 15-19.
76. Gonzalez PA, Carreno LJ, Figueroa CA, et al. Modulation of immunological synapse by membrane-bound and soluble ligands. Cytokine & Growth Factor Reviews 2007; 18: 19-31.
77. Kauth M, Grage-Griebenow E, Rohde G, et al. Synergistically upregulated interleukin-10 production in cocultures of monocytes and T cells after stimulation with respiratory syncytial virus. International Archives of Allergy and Immunology 2007; 142: 116-126.
78. Ostler T, Pircher H, Ehl S. "Bystander" recruitment of systemic memory T cells delays the immune response to respiratory virus infection. European Journal of Immunology 2003; 33: 1839-1848.
79. Sutton TC, Tayyari F, Khan MA, et al. T helper 1 background protects against airway hyperresponsiveness and inflammation in guinea pigs with persistent respiratory syncytial virus infection. Pediatric Research 2007; 61: 525-529.
80. Monick MM, Powers LS, Hassan I, et al. Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. Journal of Immunology 2007; 179: 1648-1658.
81. Byeon JH, Lee JC, Choi IS, et al. Comparison of cytokine responses in nasopharyngeal aspirates from children with viral lower respiratory tract infections. Acta Paediatrica 2009; 98: 725-730.
82. Bermejo-Martin JF, Garcia-Arevalo MC, De Lejarazu RO, et al. Predominance of Th2 cytokines, CXC chemokines and innate immunity mediators at the mucosal level during severe respiratory syncytial virus infection in children. European Cytokine Network 2007; 18: 162-167.
83. Shimojo N, Katsuki T, Tateno N, et al. T helper lymphocyte response to respiratory syncytial virus and its components in patients with respiratory allergy and nonatopic controls. International Archives of Allergy and Immunology 2008; 147: 110-116.
84. Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease caused by functional subsets of antiviral T cells. The Journal of Experimental Medicine 1994; 179: 81-89.
85. Castilow EM, Meyerholz DK, Varga SM. IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. Journal of Immunology 2008; 180: 2376-2384.
86. Fischer JE, Johnson JE, Kuli-Zade RK, et al. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. Journal of Virology 1997; 71: 8672-8677.
87. Johnson TR, Rothenberg ME, Graham BS. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+T cells in mice immunized with respiratory syncytial virus G glycoprotein. Journal of Leukocyte Biology 2008; 84: 748-759.
88. Dodd JS, Lum E, Goulding J, et al. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. Journal of Immunology 2009; 183: 7006-7013.
89. Cyr SL, Jones T, Stoica-Popescu I, et al. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine 2007; 25: 5378-5389.
90. Bukreyev A, Belyakov IM, Berzofsky JA, et al. Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. Journal of Virology 2001; 75: 12128-12140.
91. Bukreyev A, Whitehead SS, Prussin C, et al. Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines. Journal of Virology 2000; 74: 7151-7157.
92. Voges B, Vallbracht S, Zimmer G, et al. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies. Cellular Immunology 2007; 247: 85-94.
93. Weiss KA, Christiaansen AF, Fulton RB, et al. Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. Journal of Immunology 2011; 187: 3145-3154.
94. Jiang XB, Wang ZD, Zhu Y, et al. Inhibition of CD8+ T lymphocytes attenuates respiratory syncytial virus-enhanced allergic inflammation. Respiration 2009; 77: 76-84.
95. Liu J, Ruckwardt TJ, Chen M, et al. Epitope-specific regulatory CD4 T cells reduce virus-induced illness while preserving CD8 T-cell effector function at the site of infection. Journal of Virology 2010; 84: 10501-10509.
96. Ruckwardt TJ, Bonaparte KL, Nason MC, et al. Regulatory T cells promote early influx of CD8+ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. Journal of Virology 2009; 83: 3019-3028.
97. Lee DC, Harker JA, Tregoning JS, et al. CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. Journal of Virology 2010; 84: 8790-8798.
98. Fulton RB, Meyerholz DK, Varga SM. Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. Journal of Immunology 2010; 185: 2382-2392.
99. Hancock GE, Speelman DJ, Heers K, et al. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. Journal of Virology 1996; 70: 7783-7791.
100. Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. The Journal of Experimental Medicine 1998; 188: 1967-1972.
101. Tripp RA, Jones LP, Haynes LM, et al. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nature Immunology 2001; 2: 732-738.
102. Harcourt J, Alvarez R, Jones LP, et al. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. Journal of Immunology 2006; 176: 1600-1608.
103. Arnold R, Konig B, Werchau H, et al. Respiratory syncytial virus deficient in soluble G protein induced an increased proinflammatory response in human lung epithelial cells. Virology 2004; 330: 384-397.
104. The_IMpact-RSV_Study_Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
105. Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. The Journal of Infectious Diseases 2009; 200: 439-447.
106. Miao C, Radu GU, Caidi H, et al. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. The Journal of General Virology 2009; 90: 1119-1123.
107. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. The Journal of Experimental Medicine 2002; 195: 1653-1659.
108. Herrada AA, Contreras FJ, Tobar JA, et al. Immune complex-induced enhancement of bacterial antigen presentation requires Fcgamma receptor III expression on dendritic cells. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 13402-13407.
109. Tobar JA, Gonzalez PA, Kalergis AM. Salmonella escape from antigen presentation can be overcome by targeting bacteria to Fc gamma receptors on dendritic cells. Journal of Immunology 2004; 173: 4058-4065.
110. Liu Y, Gao X, Masuda E, et al. Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes. Journal of Immunology 2006; 177: 8440-8447.
111. DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 8800-8805.
112. Zhang W, Tripp RA. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. Journal of Virology 2008; 82: 12221-12231.
113. Bitko V, Musiyenko A, Shulyayeva O, et al. Inhibition of respiratory viruses by nasally administered siRNA. Nature Medicine 2005; 11: 50-55.
114. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. American Journal of Epidemiology 1969; 89: 422-434.
115. Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. American Journal of Epidemiology 1969; 89: 405-421.
116. Connors M, Kulkarni AB, Firestone CY, et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. Journal of Virology 1992; 66: 7444-7451.
117. Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. The Journal of Experimental Medicine 2002; 196: 859-865.
118. Murphy BR, Sotnikov AV, Lawrence LA, et al. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6months after immunization. Vaccine 1990; 8: 497-502.
119. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Medicine 2009; 15: 34-41.
120. Kruijsen D, Schijf MA, Lukens MV, et al. Local innate and adaptive immune responses regulate inflammatory cell influx into the lungs after vaccination with formalin inactivated RSV. Vaccine 2011; 29: 2730-2741.
121. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nature Medicine 2006; 12: 905-907.
122. Collins PL, Murphy BR. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proceedings of the American Thoracic Society 2005; 2: 166-173.
123. Elliott MB, Pryharski KS, Yu Q, et al. Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro. Journal of Virology 2004; 78: 5773-5783.
124. Collins PL, Purcell RH, London WT, et al. Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine 1990; 8: 164-168.
125. Crowe JE Jr, Randolph V, Murphy BR. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo. Virus Research 1999; 59: 13-22.
126. Crowe JE Jr, Collins PL, London WT, et al. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 1993; 11: 1395-1404.
127. Etchart N, Baaten B, Andersen SR, et al. Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. European Journal of Immunology 2006; 36: 1136-1144.
128. Huang Y, Cyr SL, Burt DS, et al. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine. Journal of Clinical Virology 2009; 44: 287-291.
129. Xie C, He JS, Zhang M, et al. Oral respiratory syncytial virus (RSV) DNA vaccine expressing RSV F protein delivered by attenuated Salmonella Typhimurium. Human Gene Therapy 2007; 18: 746-752.
130. Haas MJ, Besieging RSV. SciBX 2009; 2: 7-9.
131. Bueno SM, Gonzalez PA, Kalergis AM. Use of genetically modified bacteria to modulate adaptive immunity. Current Gene Therapy 2009; 9: 171-184.
132. Zeng R, Zhang Z, Mei X, et al. Protective effect of a RSV subunit vaccine candidate G1F/M2 was enhanced by a HSP70-like protein in mice. Biochemical and Biophysical Research Communications 2008; 377: 495-499.